ライフサイエンスコーパス: Plasmodium falciparum malaria

1 shmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria).

2 transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria.

3 dothelium are central to the pathogenesis of Plasmodium falciparum malaria.

4 gans plays a key role in the pathogenesis of Plasmodium falciparum malaria.

5 on genetics simulators cannot suitably model Plasmodium falciparum malaria.

6 tment in pregnancy (IPTp) is used to prevent Plasmodium falciparum malaria.

7 development of an effective vaccine against Plasmodium falciparum malaria.

8 hain, protects West African children against Plasmodium falciparum malaria.

9 more effective liver-stage vaccines against Plasmodium falciparum malaria.

10 ed-species infections protect against severe Plasmodium falciparum malaria.

11 (AMA-1) is a promising vaccine candidate for Plasmodium falciparum malaria.

12 are the population most severely affected by Plasmodium falciparum malaria.

13 NF) has been linked with the pathogenesis of Plasmodium falciparum malaria.

14 tistage, multigene DNA-based vaccine against Plasmodium falciparum malaria.

15 sfunction are common complications of severe Plasmodium falciparum malaria.

16 ntly needed to stem the global resurgence of Plasmodium falciparum malaria.

17 re important mediators of protection against Plasmodium falciparum malaria.

18 with hemoglobin variants in areas of endemic Plasmodium falciparum malaria.

19 n life as a "natural vaccine" against severe Plasmodium falciparum malaria.

20 malaria, especially of chloroquine-resistant Plasmodium falciparum malaria.

21 nized NOD-scid IL-2Rgammanull mouse model of Plasmodium falciparum malaria.

22 t the effects of ID on antibody responses to Plasmodium falciparum malaria.

23 000s have dramatically reduced the burden of Plasmodium falciparum malaria.

24 amodiaquine is widely used for uncomplicated Plasmodium falciparum malaria.

25 Infants are protected against Plasmodium falciparum malaria.

26 uired to combat the spread of drug-resistant Plasmodium falciparum malaria.

27 d between Malawian children with CM and mild Plasmodium falciparum malaria.

28 oughout sub-Saharan Africa (SSA) to diagnose Plasmodium falciparum malaria.

29 cells (RBCs) contributes to pathogenesis in Plasmodium falciparum malaria.

30 apies (ACTs) threatens the global control of Plasmodium falciparum malaria.

31 in the context of acquired immunity against Plasmodium falciparum malaria.

32 -Saharan Africa in adults with uncomplicated Plasmodium falciparum malaria.

33 could be considered for rescue treatment for Plasmodium falciparum malaria.

34 otect children from severe and uncomplicated Plasmodium falciparum malaria.

35 most efficacious treatment of uncomplicated Plasmodium falciparum malaria.

36 w era in effectively treating drug-resistant Plasmodium falciparum malaria.

37 859 patients aged 6 months to 12 years with Plasmodium falciparum malaria.

38 eases and obesity, is associated with severe Plasmodium falciparum malaria.

39 rison to results of PCR for the detection of Plasmodium falciparum malaria.

40 therapy (ACT) is the first-line treatment of Plasmodium falciparum malaria.

41 could be considered for rescue treatment for Plasmodium falciparum malaria.

42 t on ART, all of whom required treatment for Plasmodium falciparum malaria.

43 sis before, during, and after infection with Plasmodium falciparum malaria.

44 bstantial reduction in deaths resulting from Plasmodium falciparum malaria.

45 ine treatment against confirmed or suspected Plasmodium falciparum malaria.

46 ered as a means to interrupt transmission of Plasmodium falciparum malaria.

47 es a serious threat to the global control of Plasmodium falciparum malaria.

48 d of care for the treatment of uncomplicated Plasmodium falciparum malaria.

49 trophil function in 58 Gambian children with Plasmodium falciparum malaria [55 (95%) with uncomplicat

50 te in Mozambican children with uncomplicated Plasmodium falciparum malaria 7 days after combination t

51 The evolution of resistance in Plasmodium falciparum malaria against most available tre

52 A total of 248 cases of severe Plasmodium falciparum malaria among children aged 3 mont

53 Plasmodium falciparum malaria, an infectious disease cau

54 se-control study of 996 children with severe Plasmodium falciparum malaria and 1220 community control

55 ignificant protection against infection with Plasmodium falciparum malaria and also against clinical

56 Coinfection with Plasmodium falciparum malaria and Epstein-Barr virus (EB

57 n Africa for the management of uncomplicated Plasmodium falciparum malaria and for chemoprevention st

58 plasma samples from patients with confirmed Plasmodium falciparum malaria and in human whole-blood s

59 The contemporary spatial limits of Plasmodium falciparum malaria and its endemicity within

60 one that is widely used to prevent and clear Plasmodium falciparum malaria and Pneumocystis jirovecii

61 used to parameterize mechanistic models for Plasmodium falciparum malaria and reliably predict the e

62 In vitro growth of Toxoplasma gondii, Plasmodium falciparum (malaria) and Cryptosporidium parv

63 ratory distress (238 with pneumonia, 41 with Plasmodium falciparum malaria, and 14 with both).

64 disease, previous history of preterm birth, Plasmodium falciparum malaria, and any helmintic infecti

65 ty to most NTDs neglected tropical diseases, Plasmodium falciparum malaria, and enteric pathogens, bu

66 stance is a major obstacle to the control of Plasmodium falciparum malaria, and its origins and modes

67 blood mononuclear cells) to the liver-stage Plasmodium falciparum malaria antigen ME-TRAP.

68 Both EBV and Plasmodium falciparum malaria are cofactors in the etiol

69 le cell traits confer protection from severe Plasmodium falciparum malaria are not yet fully elucidat

70 e public health and economic consequences of Plasmodium falciparum malaria are once again regarded as

71 Protective antibodies in Plasmodium falciparum malaria are only acquired after ye

72 Characteristic features of Plasmodium falciparum malaria are polyclonal B cell acti

73 , BinaxNOW initially misclassified a case of Plasmodium falciparum malaria as non-falciparum.

74 1 (AMA1) is a leading vaccine candidate for Plasmodium falciparum malaria, as antibodies against rec

75 group has relatively better protection from Plasmodium falciparum malaria, as reflected by fewer sym

76 breast milk correlated with mothers who had Plasmodium falciparum malaria at delivery.

77 nce of the spatiotemporal prevalence of both Plasmodium falciparum malaria-attributable and non-malar

78 alling is essential for the proliferation of Plasmodium falciparum malaria blood stage parasites.

79 ay of the current treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spr

80 Artesunate is a vital therapy for Plasmodium falciparum malaria, but artesunate tablets ha

81 ne treatment recommended by the WHO to treat Plasmodium falciparum malaria, but clinical resistance a

82 ait (HbAS) is known to be protective against Plasmodium falciparum malaria, but it is unclear when du

83 e highly effective at treating uncomplicated Plasmodium falciparum malaria, but the emergence of the

84 ncy is believed to confer protection against Plasmodium falciparum malaria, but the precise nature of

85 howed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to as

86 le-cell trait) or HbC (HbAC) protect against Plasmodium falciparum malaria by unclear mechanisms.

87 Genomic surveillance of Plasmodium falciparum malaria can provide policy-relevan

88 data remain too weak to accurately enumerate Plasmodium falciparum malaria cases.

89 icant peaks in 2010; examples were increased Plasmodium falciparum malaria (chi(2)=37.57, p<0.001); i

90 associated with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria coinfections.

91 bC) are well known to protect against severe Plasmodium falciparum malaria, conclusive evidence on th

92 Plasmodium falciparum malaria contributes to a significa

93 port planning, monitoring and evaluation for Plasmodium falciparum malaria control.

94 Plasmodium falciparum malaria detected at delivery in pe

95 In Plasmodium falciparum malaria, determination of which ce

96 The majority of Plasmodium falciparum malaria diagnoses in Africa are ma

97 Plasmodium falciparum malaria dominates throughout sub-S

98 land, Oreg.), to detect Plasmodium vivax and Plasmodium falciparum malaria during an outbreak in Hond

99 PM increases MMc and that MMc alters risk of Plasmodium falciparum malaria during infancy.

100 e a significant negative association between Plasmodium falciparum malaria endemicity and LTL while a

101 In Plasmodium falciparum malaria, erythrocyte invasion by c

102 Severe Plasmodium falciparum malaria evolves through the interp

103 tive, first-line treatment for uncomplicated Plasmodium falciparum malaria, except in the first trime

104 ersion and gender, household size, or recent Plasmodium falciparum malaria exposure.

105 Malaria Meta-Signature, which discriminates Plasmodium falciparum malaria from uninfected controls;

106 ce and accuracy across benchmark datasets of Plasmodium falciparum malaria genomes.

107 Chloroquine (CQ)-resistant Plasmodium falciparum malaria has been a global health c

108 The spread of drug-resistant Plasmodium falciparum malaria has been a major impedimen

109 ntury, successful antifolate therapy against Plasmodium falciparum malaria has been attributed to hos

110 Plasmodium falciparum malaria has been found to blunt er

111 Vaccine development in human Plasmodium falciparum malaria has been hampered by the e

112 in regulating host immunity in children with Plasmodium falciparum malaria has not previously been re

113 Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an

114 ens may be able to confer protection against Plasmodium falciparum malaria; however, a technology for

115 isinins have revolutionized the treatment of Plasmodium falciparum malaria; however, resistance threa

116 gold standard choice to treat uncomplicated Plasmodium falciparum malaria; however, they are hydroph

117 Plasmodium falciparum malaria importation from Africa to

118 n dengue hemorrhagic fever in Bangkok and of Plasmodium falciparum malaria in a highland area of west

119 complicated treatment and chemoprevention of Plasmodium falciparum malaria in Africa.

120 al involving 210 children with uncomplicated Plasmodium falciparum malaria in Blantyre, Malawi.

121 nation therapy (ACT) for multidrug-resistant Plasmodium falciparum malaria in Cambodia because of few

122 09, 687 of 2885 patients (23.8%) treated for Plasmodium falciparum malaria in clinical studies in Mya

123 a urine malaria test (UMT) for diagnosis of Plasmodium falciparum malaria in febrile patients.

124 r prime-boost vaccination approaches against Plasmodium falciparum malaria in humans.

125 attributed to the resistance it provides to Plasmodium falciparum malaria in its heterozygous state,

126 ed individuals with concomitant asymptomatic Plasmodium falciparum malaria in Mali.

127 s have successfully reduced the incidence of Plasmodium falciparum malaria in many areas, there has b

128 Congenital Plasmodium falciparum malaria in newborns is uncommon in

129 and HbAC are hypothesized to protect against Plasmodium falciparum malaria in part by enhancing natur

130 s the first-line treatment for uncomplicated Plasmodium falciparum malaria in response to failing SP

131 ual spraying and other interventions against Plasmodium falciparum malaria in seasonal settings in Af

132 The emergence of multidrug-resistant Plasmodium falciparum malaria in Southeast Asia (SEA) ha

133 misinin, has been described in patients with Plasmodium falciparum malaria in southeast Asia.

134 nd efficacy of AL for treating uncomplicated Plasmodium falciparum malaria in Tanzania in 2022.

135 he recent emergence of artemisinin-resistant Plasmodium falciparum malaria in western Cambodia could

136 The incidence of Plasmodium falciparum malaria (including mixed infection

137 able malaria transmission, susceptibility to Plasmodium falciparum malaria increases during first pre

138 As the prevalence of artemisinin-resistant Plasmodium falciparum malaria increases in the Greater M

139 nstrate this with four examples: identifying Plasmodium falciparum malaria-infected erythrocytes in a

140 ia (CM) is a severe clinical complication of Plasmodium falciparum malaria infection and is character

141 aged 6 months to 14 years were assessed for Plasmodium falciparum malaria infection by rapid diagnos

142 The RTS,S/AS01 vaccine against Plasmodium falciparum malaria infection completed phase

143 We initially modelled prevalence of Plasmodium falciparum malaria infection in children aged

144 The rapid and accurate diagnosis of Plasmodium falciparum malaria infection is an essential

145 Plasmodium falciparum malaria infection is associated wi

146 Best-fit models of Plasmodium falciparum malaria infection prevalence among

147 e most effective treatment for uncomplicated Plasmodium falciparum malaria infection.

148 evalence of PCR-confirmed non-falciparum and Plasmodium falciparum malaria infections within a longit

149 During Plasmodium falciparum malaria infections, von Willebrand

150 L) are Epstein-Barr virus (EBV) and repeated Plasmodium falciparum malaria infections.

151 l parasite load and the clinical severity of Plasmodium falciparum malaria infections.

152 The pathogenesis of severe Plasmodium falciparum malaria involves cytoadhesive micr

153 Plasmodium falciparum malaria is a deadly infectious dis

154 Plasmodium falciparum malaria is a major cause of death

155 Severe Plasmodium falciparum malaria is a major cause of death

156 Chloroquine-resistant Plasmodium falciparum malaria is a major health problem,

157 Fatal Plasmodium falciparum malaria is accompanied by systemic

158 Plasmodium falciparum malaria is an important cause of m

159 Acidosis in severe Plasmodium falciparum malaria is associated with high mo

160 Much of the virulence of Plasmodium falciparum malaria is caused by cytoadherence

161 Cerebral Plasmodium falciparum malaria is characterized by adhesi

162 Plasmodium falciparum malaria is characterized by the po

163 a disease is important for understanding how Plasmodium falciparum malaria is controlled.

164 Although the burden of Plasmodium falciparum malaria is gradually declining in

165 Plasmodium falciparum malaria is increasingly difficult

166 Acquired immunity to Plasmodium falciparum malaria is mainly mediated by immu

167 Antigenic variation in Plasmodium falciparum malaria is mediated by transcripti

168 Immunity to Plasmodium falciparum malaria is naturally acquired in i

169 and vaccine-induced immunity to blood-stage Plasmodium falciparum malaria is of long-standing intere

170 g pregnant women with protective immunity to Plasmodium falciparum malaria is often dominated by VAR2

171 Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in s

172 In areas where Plasmodium falciparum malaria is seasonal, a dry season

173 The development of clinical immunity to Plasmodium falciparum malaria is thought to require year

174 -based combination therapies (ACTs) to treat Plasmodium falciparum malaria is threatened by resistanc

175 Plasmodium falciparum malaria is widespread in the tropi

176 lability and accuracy of our software on 245 Plasmodium falciparum malaria isolates from three contin

177 uitoes, the world's most important vector of Plasmodium falciparum malaria, locate their human hosts

178 dren, aged 3 months to 14 years, with severe Plasmodium falciparum malaria matched to uncomplicated m

179 emisinin-based combination therapy (ACT) for Plasmodium falciparum malaria may be threatened by paras

180 Life-threatening diseases, such as Plasmodium falciparum malaria, melioidosis, and African

181 (ACTs) have led to a significant decrease in Plasmodium falciparum malaria mortality.

182 A multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread a

183 Plasmodium falciparum malaria originated in Africa and b

184 Plasmodium falciparum malaria originated when Plasmodium

185 Genome analysis of the Plasmodium falciparum malaria parasite already is identi

186 Each Plasmodium falciparum malaria parasite carries about 50

187 -specific system of genetic integration into Plasmodium falciparum malaria parasite chromosomes.

188 independent host-parasite interaction in the Plasmodium falciparum malaria parasite invasion of RBCs.

189 ortholog of Pfs47, a protein that allows the Plasmodium falciparum malaria parasite to evade mosquito

190 and anti-malarial resistance has enabled the Plasmodium falciparum malaria parasite to inflict high m

191 e pathology associated with infection by the Plasmodium falciparum malaria parasite.

192 stereomers 5a and 5c showed activity against Plasmodium falciparum malaria parasites (IC50 approximat

193 abolic output of the apicoplast organelle in Plasmodium falciparum malaria parasites and is required

194 tanding the genomic diversity of circulating Plasmodium falciparum malaria parasites can assist infec

195 Accordingly, Plasmodium falciparum malaria parasites can be killed by

196 Plasmodium falciparum malaria parasites carry approximat

197 Plasmodium falciparum malaria parasites export the prote

198 K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria parasites has led to wides

199 opy to investigate structural development of Plasmodium falciparum malaria parasites in normal and ge

200 ization has been implicated in the growth of Plasmodium falciparum malaria parasites in their Anophel

201 It is unknown whether the presence of Plasmodium falciparum malaria parasites in umbilical cor

202 Plasmodium falciparum malaria parasites invade and multi

203 Plasmodium falciparum malaria parasites invade and remod

204 Immunization with live-attenuated Plasmodium falciparum malaria parasites is an alternativ

205 Since their first detection in 2010, Plasmodium falciparum malaria parasites lacking the P. f

206 In contrast, the mitochondrion of Plasmodium falciparum malaria parasites lacks FASII enzy

207 Transmission of Plasmodium falciparum malaria parasites occurs when noct

208 These districts border Myanmar which harbors Plasmodium falciparum malaria parasites resistant to art

209 Antigenic variation in Plasmodium falciparum malaria parasites results from swi

210 Here we show that erythrocyte-stage Plasmodium falciparum malaria parasites spontaneously ta

211 Increasing resistance of Plasmodium falciparum malaria parasites to chloroquine a

212 of a cell-free lysate prepared from asexual Plasmodium falciparum malaria parasites to remove uracil

213 Plasmodium falciparum malaria parasites were transformed

214 high antimalarial potencies in vitro against Plasmodium falciparum malaria parasites, and furans 5a a

215 and evaluate their resistance to invasion by Plasmodium falciparum malaria parasites.

216 ein, fatty acids, anionic phospholipids, and Plasmodium falciparum malaria parasitized erythrocytes.

217 Severe anemia is a lethal complication of Plasmodium falciparum malaria, particularly in children.

218 t surface antigens play an important role in Plasmodium falciparum malaria pathogenesis and in immune

219 3 (SOD3) was significantly elevated in both Plasmodium falciparum malaria patients and mice infected

220 uinone that is used therapeutically to treat Plasmodium falciparum malaria, Pneumocystis carinii pneu

221 ne that is used therapeutically for treating Plasmodium falciparum malaria, Pneumocystis jirovecii pn

222 rammatic use of the R21/Matrix-M vaccine for Plasmodium falciparum malaria prevention in children liv

223 Plasmodium falciparum malaria remains a devastating publ

224 Plasmodium falciparum malaria remains a global public he

225 Severe Plasmodium falciparum malaria remains a leading cause of

226 Plasmodium falciparum malaria remains a leading cause of

227 Plasmodium falciparum malaria remains a major cause of i

228 Plasmodium falciparum malaria remains a major public hea

229 Plasmodium falciparum malaria remains a significant glob

230 Plasmodium falciparum malaria remains one of the world's

231 The pathogenesis of coma in severe Plasmodium falciparum malaria remains poorly understood.

232 f adjunct or anti-disease therapy for severe Plasmodium falciparum malaria requires cellular and mole

233 Chloroquine resistance in Plasmodium falciparum malaria results from mutations in

234 umefantrine is widely used for uncomplicated Plasmodium falciparum malaria; sulfadoxine-pyrimethamine

235 Naturally acquired protective immunity to Plasmodium falciparum malaria takes years to develop.

236 Most rapid diagnostic tests for Plasmodium falciparum malaria target the Histidine-Rich

237 ally conducted to identify studies on severe Plasmodium falciparum malaria that included information

238 primary marker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-te

239 Plasmodium falciparum malaria, the most lethal form of h

240 ut on 279 children with severe anemia due to Plasmodium falciparum malaria; the results were similar

241 n G6PD deficiency and severe and complicated Plasmodium falciparum malaria through a case-control stu

242 Emergence of CQ drug-resistant Plasmodium falciparum malaria throughout endemic areas o

243 The emergence and spread of resistance in Plasmodium falciparum malaria to artemisinin combination

244 a mathematical model of the transmission of Plasmodium falciparum malaria to explore the potential e

245 alyses comparing clinical subtypes of severe Plasmodium falciparum malaria to matched controls with u

246 ation therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes.

247 sed malaria elimination project to interrupt Plasmodium falciparum malaria transmission in a rural di

248 ng progress has been seen with reductions in Plasmodium falciparum malaria transmission in some parts

249 Zambia has experienced a dramatic decline in Plasmodium falciparum malaria transmission in the past d

250 a were analyzed with network analysis tools, Plasmodium falciparum malaria transmission maps, and glo

251 Pfs28 is a Plasmodium falciparum malaria transmission-blocking vacc

252 returned to the UK from Uganda in 2022 with Plasmodium falciparum malaria, twice failed treatment wi

253 Anopheles gambiae mosquitoes that transmit Plasmodium falciparum malaria use a series of olfactory

254 es gambiae mosquito, which is the vector for Plasmodium falciparum malaria, uses a series of olfactor

255 te load in individual subjects infected with Plasmodium falciparum malaria, using only data obtained

256 The development of an efficacious Plasmodium falciparum malaria vaccine remains a top prio

257 ein homologue 5 (RH5), a leading blood-stage Plasmodium falciparum malaria vaccine target, interacts

258 T molecular marker for chloroquine-resistant Plasmodium falciparum malaria was retrospectively measur

259 l bloodstream infection and 35 children with Plasmodium falciparum malaria were analyzed using protei

260 Adult patients (n = 28) with severe Plasmodium falciparum malaria were enrolled in a prospec

261 Adults with Plasmodium falciparum malaria were randomized to receive

262 erapy on transmission, Gambian children with Plasmodium falciparum malaria were treated with standard

263 f uncomplicated malaria, and 687 episodes of Plasmodium falciparum malaria were treated with study dr

264 A total of 577 episodes of uncomplicated Plasmodium falciparum malaria were treated with study dr

265 Reads from Plasmodium falciparum (malaria) were detected in 21 pati

266 ogy, and not least in protective immunity to Plasmodium falciparum malaria, where key antigens show s

267 Jaundice is a common presentation of Plasmodium falciparum malaria, which arises from the acc

268 A subunit vaccine for Plasmodium falciparum malaria will need to contain well-

269 predict which of the children infected with Plasmodium falciparum malaria will progress to CM.

270 , 48, and 72 hours) in African children with Plasmodium falciparum malaria with a prespecified delta

271 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantri

272 causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity wo

273 the influence of climate on the incidence of Plasmodium falciparum malaria worldwide and how it might

274 dely-recommended treatment for uncomplicated Plasmodium falciparum malaria worldwide.

275 endemic areas, children suffer the most from Plasmodium falciparum malaria, yet newborns and young in